Physician profile
Moises E Hernandez
NPI 1134223670
$7,122.51
in general payments reported to CMS, 2019-2025
34 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $706 · 2021: $1,090 · 2022: $1,522 · 2023: $949 · 2024: $1,259 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $933.12 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $494.15 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $435.40 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $407.03 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $376.20 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $316.90 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $297.25 | 2019-2024 | |
| Madrigal Pharmaceuticals | $273.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $271.46 | 2020-2023 | Talicia |
| Intercept Pharmaceuticals, INC. | $219.69 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $218.73 | 2023-2025 | Voquezna |
| Janssen Biotech, INC. | $207.10 | 2022-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $170.16 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $128.38 | 2024-2025 | Zenpep |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $91.56 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $88.07 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $86.43 | 2022 | |
| Gilead Sciences, INC. | $76.30 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $71.66 | 2019-2022 | |
| Evoke Pharma, INC. | $64.03 | 2023-2025 | Gimoti |
| Vivus LLC | $51.97 | 2021-2024 | Pancreaze, Qsymia |
| Braintree Laboratories, INC. | $49.11 | 2021-2024 | Sutab |
| Nestle Healthcare Nutrition INC. | $49.07 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $47.68 | 2022-2024 | Givlaari |
| Covidien Lp | $42.17 | 2019 | |
| Allergan, INC. | $34.94 | 2020 | |
| Alfasigma USA, INC. | $32.78 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.86 | 2022 | |
| Romark Laboratories, Lc | $16.89 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $14.69 | 2021 | |
| Pfizer INC. | $14.55 | 2025 | |
| Concordia Pharmaceuticals INC. | $13.13 | 2019 | |
| Pentax of America, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.